The Relationship Between Symptom Severity and Symptom Interference, Education, Age, Marital Status, and Type of Chemotherapy Treatment in Israeli Women With Early-Stage Breast Cancer

2010 ◽  
Vol 37 (6) ◽  
pp. E411-E418 ◽  
Author(s):  
Ayelet Prigozin ◽  
Beatrice Uziely ◽  
Catherine F. Musgrave
Keyword(s):  
Breast Cancer ◽  
Marital Status ◽  
Symptom Severity ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Chemotherapy Treatment ◽  
The Relationship

Impact of African ancestry on the relationship between BMI and survival in early stage breast cancer: Retrospective analysis from E5103.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 1010-1010
Author(s):  
Tarah Jean Ballinger ◽  
Guanglong Jiang ◽  
Fei Shen ◽  
Kathy Miller ◽  
Bryan P. Schneider
Keyword(s):  
Breast Cancer ◽  
Racial Disparities ◽  
Early Stage ◽  
African Ancestry ◽  
Genetic Ancestry ◽  
Early Stage Breast Cancer ◽  
European Ancestry ◽  
A Genome ◽  
The Impact ◽  
The Relationship

1010 Background: Both Black race and obesity are associated with worse survival in early stage breast cancer. Obesity disproportionately affects Black women; however, the degree this contributes to racial disparities in breast cancer remains unclear. Prior work evaluated heterogeneous populations or used self- reported race, rather than genetic ancestry. African ancestry is associated with higher BMI and worse survival in breast cancer; however, the intersection between genetic ancestry and obesity on survival outcomes remains unknown. Methods: We analyzed data from the adjuvant trial E5103. Patients with high risk, HER2 negative breast cancer received doxorubicin/cyclophosphamide x 4, followed by weekly paclitaxel x 12, with or without bevacizumab. Genetic ancestry was determined on the 2,854 patients with available germline DNA, BMI, and outcome data using principal components from a genome-wide array. The primary objective assessed impact of BMI on DFS and OS by ancestry. Multivariate Cox proportional hazard models evaluated correlation between continuous or binary BMI and survival in African (AA) and European (EA) Americans. Results: 13.4% of patients were genetically classified as AA and 86.6% as EA. Higher continuous BMI was significantly associated with worse DFS and OS only in AAs (DFS: HR = 1.25 95% CI 1.07-1.46, p = 0.004; OS: HR = 1.38 95% CI 1.10-1.73, p = 0.005); not in EAs (DFS HR = 0.97 95% CI 0.90-1.05, p = 0.50; OS HR = 1.03 95% CI 0.93-1.14, p = 0.52). By disease subtype, BMI was associated with worse outcomes only in AAs with ER+, and not TNBC. By categorical BMI, WHO class III obesity (³ 40) significantly associated with worse DFS and OS only in AAs (DFS HR = 1.98, p = 0.010; OS HR = 2.07, p = 0.064), not in EAs (DFS HR = 0.97, p = 0.86; OS HR = 1.28, p = 0.30). Proportion of African ancestry (proAA) was associated with higher BMI and worse outcomes in the total population; however, within AAs there was no significant interaction between proAA and BMI on DFS (HR = 0.36, p = 0.06) or OS (HR = 0.38, p = 0.24). In AAs, BMI remained associated with DFS (HR = 2.78, p = 0.019), suggesting higher BMI is associated with worse DFS regardless of proAA. Coefficients for the interaction term indicate that as proAA increases the impact of BMI on outcome is lessened. Conclusions: Higher BMI is significantly associated with worse breast cancer outcomes in women of African ancestry in E5103, but not in those of European ancestry. Categorically, this association was significant only for severe obesity, indicating the relationship may depend on the degree of obesity. As proAA increased in AAs, the impact of BMI on outcome was lessened, suggesting other host factors may contribute more to obesity’s influence on outcome than genetics. Determination of the optimal populations for weight loss interventions will advance precision medicine efforts to impact racial disparities and outcomes in early stage breast cancer.

The relationship between surgical factors and margin status after breast-conservation surgery for early stage breast cancer

2009 ◽  
Vol 197 (6) ◽  
pp. 740-746 ◽  
Author(s):  
Peter J. Lovrics ◽  
Sylvie D. Cornacchi ◽  
Forough Farrokhyar ◽  
Anna Garnett ◽  
Vicky Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Early Stage ◽  
Breast Conservation ◽  
Margin Status ◽  
Early Stage Breast Cancer ◽  
Breast Conservation Surgery ◽  
Conservation Surgery ◽  
The Relationship

scholarly journals Population-based study of the relationship of treatment and sociodemographics on quality of life for early stage breast cancer

2005 ◽  
Vol 14 (6) ◽  
pp. 1467-1479 ◽  
Author(s):  
Nancy K. Janz ◽  
Mahasin Mujahid ◽  
Paula M. Lantz ◽  
Angela Fagerlin ◽  
Barbara Salem ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Early Stage ◽  
Population Based ◽  
Early Stage Breast Cancer ◽  
Population Based Study ◽  
Relationship Of ◽  
The Relationship

scholarly journals Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay

2019 ◽  
pp. 1-10
Author(s):  
Hatem Soliman ◽  
Darl D. Flake ◽  
Anthony Magliocco ◽  
Mark Robson ◽  
Lee Schwartzberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Early Stage ◽  
Growth Factor Receptor ◽  
Distant Recurrence ◽  
Early Stage Breast Cancer ◽  
Chemotherapy Treatment ◽  
Absolute Benefit ◽  
Estrogen Receptor Positive ◽  
Epidermal Growth

PURPOSE Previous studies have shown EndoPredict (EPclin), a test that integrates 12-gene expression data with nodal status and tumor size, to be predictive for risk of distant recurrence in women with estrogen receptor–positive, human epidermal growth factor receptor 2–negative early-stage breast cancer. Here, we modeled expected absolute chemotherapy benefit on the basis of EPclin test results. METHODS The effect of chemotherapy was modeled using previously validated 10-year risk of distant recurrence as a function of EPclin score for patients treated without chemotherapy. Average relative chemotherapy benefit to reduce breast cancer distant recurrence was evaluated using a published meta-analysis from the Early Breast Cancer Trialists’ Collaborative Group. Absolute chemotherapy benefit differences were estimated across a range of interaction strengths between relative chemotherapy benefit and EPclin score. The average absolute benefit was calculated for patients with high and low EPclin scores using the distribution of scores in 2,185 samples tested by Myriad Genetics. RESULTS The average expected absolute benefit of chemotherapy treatment for patients with a low EPclin score was 1.8% in the absence of interaction and 1.5% for maximal interaction. Conversely, the expected average absolute chemotherapy benefit for patients with a high EPclin score was 5.3% and 7.3% for no interaction and maximal interaction, respectively. CONCLUSION For women with estrogen receptor–positive, human epidermal growth factor receptor 2–negative early-stage breast cancer, a high EPclin score identified which patients would benefit most from adjuvant chemotherapy in terms of absolute reduction of distant recurrence, regardless of the amount of interaction between EPclin and relative chemotherapy benefit. A high degree of prognostic discrimination for distant recurrence is more important for identifying patients likely to benefit most from chemotherapy than an interaction between EPclin and treatment-relative benefit.

Sign in / Sign up

Export Citation Format

Share Document